Actively Recruiting
SB17170 Phase 2 Trial in IPF Patients
Led by SPARK Biopharma · Updated on 2025-11-19
30
Participants Needed
5
Research Sites
91 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to moderate to severe patients with IPF. This clinical trial treatment involves administering SB17170 or placebo for 12 weeks.
CONDITIONS
Official Title
SB17170 Phase 2 Trial in IPF Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 40 years or older at the time of consent
- Diagnosed with idiopathic pulmonary fibrosis confirmed by chest HRCT scan
- Confirmed Usual Interstitial Pneumonia (UIP) or probable UIP pattern on chest HRCT before baseline
- History of idiopathic pulmonary fibrosis treatment meeting study criteria
- Forced Vital Capacity (FVC) of 45% or higher of predicted normal value at screening
- Meets pulmonary function test criteria at screening
- Voluntarily agrees and signs informed consent form
You will not qualify if you...
- Presence of primary diseases showing UIP patterns such as rheumatoid arthritis-related or connective tissue disease-related interstitial lung disease
- Acute exacerbation of IPF within 6 months before screening or during screening
- Lower respiratory tract infections requiring antibiotic treatment
- Major surgery within 3 months before screening or planned during the trial
- History or evidence of active or suspected malignancy within 5 years prior to screening
- Evidence of active infection
- Cardiovascular or cerebrovascular diseases including severe hypertension (within 3 months), myocardial infarction or unstable angina (within 6 months), thrombotic events (within 6 months), or heart failure diagnosis (within 6 months)
- Pulmonary hypertension
- Unable to take drugs orally or history of major gastrointestinal surgery or conditions affecting drug absorption
- Infection with HIV or active hepatitis B or C
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Myong Ji Hospital
Goyang, South Korea
Actively Recruiting
2
Chung-Ang University Gwangmyeong Hospital
Gwangmyeong, South Korea
Actively Recruiting
3
Seoul Asan Hospital
Seoul, South Korea
Not Yet Recruiting
4
The Catholic Univ. of Korea Seoul St. Mary's Hospital
Seoul, South Korea
Not Yet Recruiting
5
Ajou University Hospital
Suwon, South Korea
Not Yet Recruiting
Research Team
S
Seong Yun Bang
CONTACT
Y
Yu Jin Choi
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here